% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Makhov:84831,
      author       = {Makhov, V. N. and Kirm, M. and Stryganyuk, G. and
                      Vielhauer, S. and Zimmerer, G. and DESY},
      title        = {{VUV} luminescence due to 5d-4f transitions in ${G}d^{3+}$
                      and ${L}u^{3+}$ ions doped into fluoride crystals},
      journal      = {ECS transactions},
      volume       = {11},
      issn         = {1938-5862},
      address      = {Pennington, NJ},
      publisher    = {Electrochemical Society (ECS)},
      reportid     = {PHPPUBDB-8392},
      pages        = {1-10},
      year         = {2008},
      abstract     = {This open-label extension evaluated the long-term efficacy
                      and tolerability of rufinamide in patients with
                      Lennox-Gastaut syndrome (LGS) who had previously completed a
                      12-week double-blind study.In total, 124 patients (aged 4-37
                      years), receiving 1-3 concomitant antiepileptic drugs, were
                      treated with rufinamide approximately 25-60 mg/kg/day.
                      Efficacy was assessed by seizure frequency; tolerability by
                      adverse events (AEs) and laboratory tests.Overall, patients
                      were treated with rufinamide for a median (range) of 432
                      (10-1149) days. Reductions in seizure frequency were
                      observed throughout the study; during the last 12 months of
                      treatment, $41.0\%$ and $47.9\%$ of patients had > or =
                      $50\%$ reduction in total and tonic-atonic seizure
                      frequency, respectively. The most common AEs were vomiting
                      $(30.6\%)$ and pyrexia $(25.8\%).In$ this open-label
                      extension, rufinamide appeared to be an effective long-term
                      adjunctive therapy for the treatment of LGS-associated
                      seizures in children and young adults.},
      keywords     = {Adolescent / Adult / Anticonvulsants: therapeutic use /
                      Child / Child, Preschool / Double-Blind Method / Drug
                      Evaluation / Drug Therapy, Combination: methods / Epilepsy:
                      drug therapy / Female / Humans / Longitudinal Studies / Male
                      / Treatment Outcome / Triazoles: therapeutic use / Young
                      Adult / Anticonvulsants (NLM Chemicals) / Triazoles (NLM
                      Chemicals) / rufinamide (NLM Chemicals)},
      cin          = {HASYLAB},
      ddc          = {540},
      cid          = {$I:(DE-H253)HASYLAB_-2012_-20130307$},
      pnm          = {DORIS Beamline I (POF1-550) / FS-Proposal: II-20042040 EC
                      (II-20042040-EC)},
      pid          = {G:(DE-H253)POF1-I-20130405 / G:(DE-H253)II-20042040-EC},
      experiment   = {EXP:(DE-H253)D-I-20150101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:20199521},
      UT           = {WOS:00},
      doi          = {10.1149/1.2929812},
      url          = {https://bib-pubdb1.desy.de/record/84831},
}